Navigation Links
Bayer HealthCare Presents Florbetaben Phase II Study Results at World Congress of Neurology
Date:10/30/2009

BANGKOK, Oct. 30 /PRNewswire/ -- Bayer HealthCare presented results from a global Phase II study of florbetaben, its imaging agent in development for the detection of cerebral beta-Amyloid plaques, at the 19th World Congress of Neurology (WCN).

The purpose of the Phase II study was to investigate the efficacy of florbetaben in differentiating between patients with a clinical diagnosis of probable Alzheimer's disease and Healthy Volunteers (HVs). Participants were evaluated using visual assessment of the uptake pattern of florbetaben in the brain and its ability to detect or exclude cerebral beta-Amyloid plaques. Cerebral beta-Amyloid plaques are one of the pathological hallmarks of Alzheimer's disease.

Current diagnosis of Alzheimer's disease is based on cognitive tests that can only indicate a probability of having the disease. A definitive clinical diagnosis of Alzheimer's disease is only possible through a post-mortem autopsy or brain tissue biopsy.

Florbetaben (BAY 94-9172) is an investigational positron emission tomography (PET) imaging tracer. In the global Phase II, open-label, non-randomized, multi-center study, florbetaben was used to detect or exclude the presence of cerebral beta-Amyloid plaques. A total of 81 men and women with probable mild-to-moderate Alzheimer's disease and 69 cognitively non-impaired healthy volunteers aged 55 and older were imaged with a single intravenous injection of florbetaben. The florbetaben uptake pattern was visually assessed for all time points by three independent, nuclear medicine physicians blinded to the clinical diagnosis and all other clinical data.

Results showed that PET images using florbetaben had a specificity of approximately 90 percent. This means that the florbetaben scan indicated the presence of cerebral beta-Amyloid plaques in approximately 10 percent of the healthy volunteers. The results also showed a sensitivity of approximately 80 percent,
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Bayer and Onyx Announce Nexavar Data Presentations at 60th American Association for the Study of Liver Diseases Annual Meeting
2. Bayers Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients
3. Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress 2009
4. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
5. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
6. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
7. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
8. Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
9. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
10. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
11. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... and NEW YORK , Sept. ... SAS and the Hereditary Neuropathy Foundation (HNF) announced today ... awareness around Charcot-Marie-Tooth (CMT) disease and support the development ... Pharnext will provide financial support to several ... development of a specific section in the HNF website ...
(Date:9/15/2014)... 2014 /PRNewswire/ -  Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ... with a focus on Omega-3 therapies for cardiovascular ... Board of Directors approved the granting of stock ... close of business on Friday, September 12, 2014. ... shares of the Company were granted in accordance ...
(Date:9/15/2014)...  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... Valeant Pharmaceuticals International, will redeem all of the outstanding ... Notes due 2017, CUSIP Nos. 91911XAL8, U9098VAD4 (the " ... an irrevocable notice of redemption for the Notes. ... irrevocable notice of redemption with respect to the remaining ...
Breaking Medicine Technology:Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 2Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 3Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 4Pivotal Therapeutics Grants Incentive Stock Options 2Valeant Announces Redemption of All of the Outstanding $500.0 Million Aggregate Principal Amount of its 6.75% Senior Notes due 2017 2
... , , JERUSALEM, Israel, January 11 ... systems, today announced that it has filed two registration,statements on ... One registration statement relates to a proposed ... and warrants to purchase 12,million shares of common stock, as ...
... , SAN JOSE, Calif., Jan. 11 Finesse Solutions, ... life sciences process applications, announced the production release of ... oxygen or pH and process temperature, and TruTorr headspace ... accuracy, lifetime, and ease of use. It is available ...
Cached Medicine Technology:Oramed Pharmaceuticals Announces Filing of Two Registration Statements 2Oramed Pharmaceuticals Announces Filing of Two Registration Statements 3Single-Use Sensor Product Family Enters High Volume Production 2
(Date:9/16/2014)... (PRWEB) September 16, 2014 Synergy Research ... comprehensive report gives the best detail and analysis of ... pulled from a variety of sources, including Ministry of ... Orange Paper will give readers actionable intelligence on clinical ... Paper is relied on by the local and international ...
(Date:9/16/2014)... Florida Hospital announced today it is teaming up ... and become the Presenting Sponsor of the 2014-15 and ... and wellness partner. As the Presenting Sponsor for the ... and name inclusion on all Lightning advertising campaigns and ... been a sponsorship partner of the Lightning since 2011, ...
(Date:9/16/2014)... Whatisfinalexpenseinsurance.com has released a new ... life insurance for seniors. , Finding affordable life insurance ... big part of the insurance market has moved online. ... that clients can use when shopping for life coverage. ... important for providing financial security for vulnerable family members. ...
(Date:9/16/2014)... serve of dairy food may reduce the risk of ... foods have not traditionally formed part of the diet. ... by Emeritus Professor Mark Wahlqvist from Monash University,s Department ... Institute, considered the role increased consumption of dairy foods ... longevity. , "In a dominantly Chinese food culture, ...
(Date:9/16/2014)... 15, 2014A comparison of five-year sexual function ... external beam radiotherapy (EBRT) versus combination EBRT ... vessel-sparing radiation therapy makes cure possible without ... presented today at the American Society for ... , The study examined the patient-reported outcomes ...
Breaking Medicine News(10 mins):Health News:Synergy Research Group Debuts Ukraine Orange Paper 2Health News:Florida Hospital Teams up with the Tampa Bay Lightning as the New Presenting Sponsor of the 2014-15 and 2015-16 Lightning Seasons 2Health News:Florida Hospital Teams up with the Tampa Bay Lightning as the New Presenting Sponsor of the 2014-15 and 2015-16 Lightning Seasons 3Health News:Life Insurance for Seniors - Clients Can Find Fast Life Insurance By Comparing Online Quotes! 2Health News:A heart-felt need for dairy food 2Health News:Prostate cancer patients surveyed 5 years after vessel-sparing RT report preserved sexual function 2Health News:Prostate cancer patients surveyed 5 years after vessel-sparing RT report preserved sexual function 3
... and longevity to health status and quality of life. Researchers ... longer, but the quality of life in later years must// ... benefits of staying physically active in your later years. The ... to perform their daily activities easier later in life. ...
... for a cure for diabetes. A new study done in ... insulin producing //pancreatic islet cells. This could lead to a ... research is a follow up to the 2001 report of ... The new research focuses on the biological mechanism behind that ...
... a deterioration of the retina, is the number one cause ... significantly // reduce the number of people with vision loss ... ,A couple of years ago, researchers conducted a ... vitamins C, E, and beta carotene, along with zinc oxide ...
... lifestyle changes and medication can prevent or delay the onset ... used to identify high-risk individuals for diabetes, but the test ... of risk //factors known as metabolic syndrome is able to ... ,Metabolic syndrome has been shown to lead to the ...
... eat play a role in whether you’ll end up with ... women between //ages 20 and 40 for one year. Their ... at least eight servings of fruits or vegetables a day ... than those who ate their usual diets. ,The ...
... a historic vote Friday night on a bill that would ... // of the politically popular entitlement program in its 38-year ... have lined up in our favor," House Speaker Dennis Hastert ... time is upon us. It's now or never." ...
Cached Medicine News:Health News:Predictors for Type 2 Diabetes 2Health News:House heads for Medicare drug vote, 2Health News:House heads for Medicare drug vote, 3
... onsite test! QuickScreen multi-panel dip cards offer ... your choice of any conceivable combination of ... flexibility for your drug testing program. Just ... the built-in timer tells you when to ...
... Screen Tests are available in 14 configurations ... Designed using Microgenics Antibody Technology, the SureStep™ ... of care immunoassay targeted to detect MDMA ... and MDEA but no cross-reactivity to any ...
Accu-Stat Home Drug Test for Marijuana (THC), Cocaine (COC), Amphetamine (AMP), Methamphetamine (mAMP), Opiates (OPI), and Phencyclidine (PCP)....
... are highly accurate in detecting the presence of ... by GC/MS testing. This assay provides a preliminary ... as GC/MS) must be used in order to ... applied to any drug of abuse test result, ...
Medicine Products: